Double-blind adaptive experiment
A double-blind adaptive experiment combines two powerful design features: double-blinding, which conceals treatment assignment from both participants and outcome assessors to prevent bias, and adaptive modification, which allows pre-specified changes to the trial's course — such as sample size re-estimation, allocation ratio shifts, or arm dropping — based on accumulating interim data. The result is a rigorous, bias-protected design that can respond to emerging evidence without compromising inferential validity.
Rekodi ya chanzo
Nukuu zimehamishwa kwa uhalisi kutoka kwa rekodi ya chanzo cha mbinu. Hakuna uthibitisho wa kiwango cha dai unaodokezwa kutoka kwao.
- U.S. Food and Drug Administration. (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. FDA. · URL
- Berry, S. M., Carlin, B. P., Lee, J. J., & Muller, P. (2010). Bayesian Adaptive Methods for Clinical Trials. CRC Press. · ISBN 9781439825488
Madai yaliyotunzwa
Madai yamehifadhiwa katika daftari la ushahidi, kila moja ikiwa na tathmini yake.
Mwonekano huu haubuni tathmini ya dai wakati daftari haina yoyote.
Mbinu zinazohusiana
Zilizotengenezwa kutoka kwa grafu ya mbinu na kuonyeshwa kama uhusiano uliopendekezwa na mashine — hakuna dai la ushahidi linalodokezwa.